Ghanshyam Kharel
Ghanshyam Kharel has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ramesh Shrestha
Neurology
4 shared publications - Gaurav Nepal
Tribhuvan University Institute of Medicine
3 shared publications - Anzil Mani Singh Maharjan
Neurology, Upendra Devkota Memorial National Institute of Neurological and Allied Sciences, Kathmandu, NPL
2 shared publications - Jayant Kumar Yadav
Annapurna Neurological Institute and Allied Sciences Kathmandu Nepal
2 shared publications - Rajeev Ojha
Department of Neurology Tribhuvan University Institute of Medicine Teaching Hospital Kathmandu Nepal
2 shared publications - Rohit Pandit
TidalHealth Peninsula Regional, Internal Medicine Salisbury Maryland USA
2 shared publications
Latest Publications
- Open Access
- 30 September 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 7750-7754
Postpartum neurological mystery: a case report of tumefactive multiple sclerosis mimicking intracranial neoplasm in a lactating woman
Introduction and Importance: Tumefactive multiple sclerosis (TMS) is a rare and severe variant of MS, characterized by large, tumor-like demyelinating lesions in the central nervous system. It can present abruptly with diverse neurological symptoms, including motor deficits, seizures, visual disturbances, and speech or swallowing difficulties. Immune modulation during pregnancy and lactation may trigger or exacerbate demyelinating episodes. Radiologically, TMS often mimics neoplastic or infectious lesions, posing diagnostic challenges, particularly in regions endemic for infections such as tuberculosis. Case Presentation: A 32-year-old lactating woman presented with acute dysphagia and dysphonia. Brain magnetic resonance imaging (MRI) revealed multiple intracranial lesions initially suggestive of infection or neoplasm. Breastfeeding was discontinued, and the infant transitioned to formula feeding. Empirical antitubercular therapy was initiated, but a stereotactic biopsy confirmed TMS. The patient was treated with high-dose corticosteroids and rituximab, resulting in marked clinical improvement. Follow-up MRI at 3 months demonstrated near-complete resolution of the lesions. Discussion: TMS is a rare demyelinating condition that can closely mimic intracranial tumors or infections, often leading to delayed or inappropriate management. In postpartum women, immune system shifts may precipitate demyelinating episodes. Early histopathological confirmation is critical to guide appropriate therapy, prevent unnecessary interventions, and optimize outcomes. This case highlights the importance of considering TMS in atypical postpartum neurological presentations. Conclusion: TMS should be included in the differential diagnosis of mass-like brain lesions in postpartum women. Histopathological confirmation enables accurate diagnosis and timely initiation of immunotherapy, improving clinical and radiological outcomes.
- 30 September 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 7750-7754
Open AccessPostpartum neurological mystery: a case report of tumefactive multiple sclerosis mimicking intracranial neoplasm in a lactating woman
Introduction and Importance: Tumefactive multiple sclerosis (TMS) is a rare and severe variant of MS, characterized by large, tumor-like demyelinating lesions in the central nervous system. It can present abruptly with diverse neurological symptoms, including motor deficits, seizures, visual disturbances, and speech or swallowing difficulties. Immune modulation during pregnancy and lactation may trigger or exacerbate demyelinating episodes. Radiologically, TMS often mimics neoplastic or infectious lesions, posing diagnostic challenges, particularly in regions endemic for infections such as tuberculosis. Case Presentation: A 32-year-old lactating woman presented with acute dysphagia and dysphonia. Brain magnetic resonance imaging (MRI) revealed multiple intracranial lesions initially suggestive of infection or neoplasm. Breastfeeding was discontinued, and the infant transitioned to formula feeding. Empirical antitubercular therapy was initiated, but a stereotactic biopsy confirmed TMS. The patient was treated with high-dose corticosteroids and rituximab, resulting in marked clinical improvement. Follow-up MRI at 3 months demonstrated near-complete resolution of the lesions. Discussion: TMS is a rare demyelinating condition that can closely mimic intracranial tumors or infections, often leading to delayed or inappropriate management. In postpartum women, immune system shifts may precipitate demyelinating episodes. Early histopathological confirmation is critical to guide appropriate therapy, prevent unnecessary interventions, and optimize outcomes. This case highlights the importance of considering TMS in atypical postpartum neurological presentations. Conclusion: TMS should be included in the differential diagnosis of mass-like brain lesions in postpartum women. Histopathological confirmation enables accurate diagnosis and timely initiation of immunotherapy, improving clinical and radiological outcomes.
- Open Access
- 22 October 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (10) , omac109
A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory condition of the central nervous system caused by severe immune-mediated demyelination and axonal destruction, mainly affecting optic nerves and the spinal cord. We describe a 26-year-old Nepalese woman with recent onset of headache, nausea, vomiting and hiccups indicative of Area Postrema Syndrome (APS). The antibody test for aquaporin-4 was strongly positive. Brain magnetic resonance imaging (MRI) showed a bilateral hyperintense signal in the area postrema (AP). The patient started on methylprednisolone, and then azathioprine was added. However, the patient was readmitted because of tingling in her right upper extremity and sudden onset of tremors. An MRI scan showed an enlarged lesion in AP. Rituximab was started on top of the previous treatment, and a second dose was given after 2 weeks. The patient had been monitored regularly and symptom-free for 5 months. Hence, we emphasize the immediate need for a diagnostic approach for NMOSD management.
- 22 October 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (10) , omac109
Open AccessA case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory condition of the central nervous system caused by severe immune-mediated demyelination and axonal destruction, mainly affecting optic nerves and the spinal cord. We describe a 26-year-old Nepalese woman with recent onset of headache, nausea, vomiting and hiccups indicative of Area Postrema Syndrome (APS). The antibody test for aquaporin-4 was strongly positive. Brain magnetic resonance imaging (MRI) showed a bilateral hyperintense signal in the area postrema (AP). The patient started on methylprednisolone, and then azathioprine was added. However, the patient was readmitted because of tingling in her right upper extremity and sudden onset of tremors. An MRI scan showed an enlarged lesion in AP. Rituximab was started on top of the previous treatment, and a second dose was given after 2 weeks. The patient had been monitored regularly and symptom-free for 5 months. Hence, we emphasize the immediate need for a diagnostic approach for NMOSD management.
- Open Access
- 17 September 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 82, 104722
A case report: Lateral medullary syndrome with facial nerve palsy and hemiparesis
Lateral medullary syndrome (LMS) is the most common and severe neurological syndrome associated with atherothrombotic occlusion of the intracranial vertebral artery, followed by posterior inferior cerebellar artery and medullary artery occlusion. It presents as a typical triad of oculosympathetic palsy (Horner's syndrome), ipsilateral gait ataxia, and hypoalgesia with ipsilateral thermoanesthesia of the face.
- 17 September 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 82, 104722
Open AccessA case report: Lateral medullary syndrome with facial nerve palsy and hemiparesis
Lateral medullary syndrome (LMS) is the most common and severe neurological syndrome associated with atherothrombotic occlusion of the intracranial vertebral artery, followed by posterior inferior cerebellar artery and medullary artery occlusion. It presents as a typical triad of oculosympathetic palsy (Horner's syndrome), ipsilateral gait ataxia, and hypoalgesia with ipsilateral thermoanesthesia of the face.
- Open Access
- 6 September 2022
- Published by Springer Nature in Cureus
- Vol. 14 (9) , e28834
Clinico-Radiological Profile of Patients With Lateral Medullary Syndrome: A Five Years Observation From a Single-Centered Tertiary Hospital in Nepal
Objective: We aim to correlate the prevalence of symptoms of the lateral medullary syndrome (LMS) based on radiological classification. Methods: A five-year record of 41 patients diagnosed with LMS and admitted to a tertiary care center in Nepal was reviewed. We used chi-square tests to compare symptoms between rostral and caudal groups and different horizontal subtypes. Results: The subtype prevalence in the horizontal classification of LMS was large (31.7%), lateral (22%), dorsal (19.5%), typical (14.6%), and ventral (12.2%). The most common symptoms in the typical subtype of the horizontal classification were: pain/temperature loss in the contralateral body (7.3%) and dysphagia (7.3%); in the ventral subtype, swaying on the Romberg test (12.2%), dysarthria (9.8%) and dizziness (9.8%); in the dorsal subtype, headache (12.2%) and vomiting (12.2%). Whereas headache (22.2%) and lateropulsion on standing (14.6%), swaying on the Romberg test (14.6%), nausea/vomiting (14.6%) were common in the large subtype, and nausea/vomiting (19.5%) and headache (17.1%) in the lateral subtypes. Whereas, in rostrocaudal classification, the rostral subtype (61%) was more common than the caudal subtype (31%). There was no significant variation in symptoms based on the rostrocaudal classification of LMS. Conclusion: The common clinical manifestations are different for different radiological subtypes of LMS. Further comprehensive studies are essential to understand the prevalence of symptoms in different radiological subtypes and the clinical-radiologic correlation in LMS.
- 6 September 2022
- Published by Springer Nature in Cureus
- Vol. 14 (9) , e28834
Open AccessClinico-Radiological Profile of Patients With Lateral Medullary Syndrome: A Five Years Observation From a Single-Centered Tertiary Hospital in Nepal
Objective: We aim to correlate the prevalence of symptoms of the lateral medullary syndrome (LMS) based on radiological classification. Methods: A five-year record of 41 patients diagnosed with LMS and admitted to a tertiary care center in Nepal was reviewed. We used chi-square tests to compare symptoms between rostral and caudal groups and different horizontal subtypes. Results: The subtype prevalence in the horizontal classification of LMS was large (31.7%), lateral (22%), dorsal (19.5%), typical (14.6%), and ventral (12.2%). The most common symptoms in the typical subtype of the horizontal classification were: pain/temperature loss in the contralateral body (7.3%) and dysphagia (7.3%); in the ventral subtype, swaying on the Romberg test (12.2%), dysarthria (9.8%) and dizziness (9.8%); in the dorsal subtype, headache (12.2%) and vomiting (12.2%). Whereas headache (22.2%) and lateropulsion on standing (14.6%), swaying on the Romberg test (14.6%), nausea/vomiting (14.6%) were common in the large subtype, and nausea/vomiting (19.5%) and headache (17.1%) in the lateral subtypes. Whereas, in rostrocaudal classification, the rostral subtype (61%) was more common than the caudal subtype (31%). There was no significant variation in symptoms based on the rostrocaudal classification of LMS. Conclusion: The common clinical manifestations are different for different radiological subtypes of LMS. Further comprehensive studies are essential to understand the prevalence of symptoms in different radiological subtypes and the clinical-radiologic correlation in LMS.
- Open Access
- 3 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26520
Takayasu Arteritis Presenting As Epileptic Seizure: A Case Report
Takayasu's arteritis is a chronic granulomatous large-vessel vasculitis condition that affects the large and medium-sized arteries, primarily the heart and its major vessels. The first symptoms and indicators of Takayasu arteritis differ because the afflicted arteries are heterogeneous. Furthermore, vascular lesions might be difficult to identify at first, further complicating diagnosis. Takayasu arteritis presenting as epileptic seizures is rare. Here, we discuss a 20-year-old female who presented with a brief period of unresponsiveness, followed by a tonic stiffening, limb jerks, a postictal period of fatigue, and temporal memory loss. During the acute phase of Takayasu arteritis, high-dose glucocorticoid therapy and immunosuppressive therapy were used to control inflammatory reactions. Her symptoms gradually improved, and she was discharged from the hospital after serial monitoring; her follow-up visits revealed no recurrence.
- 3 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26520
Open AccessTakayasu Arteritis Presenting As Epileptic Seizure: A Case Report
Takayasu's arteritis is a chronic granulomatous large-vessel vasculitis condition that affects the large and medium-sized arteries, primarily the heart and its major vessels. The first symptoms and indicators of Takayasu arteritis differ because the afflicted arteries are heterogeneous. Furthermore, vascular lesions might be difficult to identify at first, further complicating diagnosis. Takayasu arteritis presenting as epileptic seizures is rare. Here, we discuss a 20-year-old female who presented with a brief period of unresponsiveness, followed by a tonic stiffening, limb jerks, a postictal period of fatigue, and temporal memory loss. During the acute phase of Takayasu arteritis, high-dose glucocorticoid therapy and immunosuppressive therapy were used to control inflammatory reactions. Her symptoms gradually improved, and she was discharged from the hospital after serial monitoring; her follow-up visits revealed no recurrence.
- Open Access
- 23 October 2020
- Published by Springer Nature in Tropical Diseases, Travel Medicine and Vaccines
- Vol. 6 (1) , 1-3
The dangers of mass drug administration of albendazole in Nepal, a Neurocysticercosis-endemic region
The majority of cases of Neurocysticercosis (NCC) are asymptomatic. Injudicious use of antihelmintics like albendazole (ALB) can cause cyst degeneration and perilesional inflammation, thus rendering asymptomatic individuals symptomatic with seizures, headache, vascular events, or cerebral edema. Mass drug administration (MDA) using ALB is a very common practice in developing countries like Nepal to contain transmission of soil-transmitted helminths (STH) and lymphatic filariasis (LF). Although the benefits of ALB-based MDA in the general population cannot be undermined, there can be severe consequences in certain groups, especially those with latent NCC. In this commentary, we discuss the effect it may have on such patients, and suggest potential solutions.
- 23 October 2020
- Published by Springer Nature in Tropical Diseases, Travel Medicine and Vaccines
- Vol. 6 (1) , 1-3
Open AccessThe dangers of mass drug administration of albendazole in Nepal, a Neurocysticercosis-endemic region
The majority of cases of Neurocysticercosis (NCC) are asymptomatic. Injudicious use of antihelmintics like albendazole (ALB) can cause cyst degeneration and perilesional inflammation, thus rendering asymptomatic individuals symptomatic with seizures, headache, vascular events, or cerebral edema. Mass drug administration (MDA) using ALB is a very common practice in developing countries like Nepal to contain transmission of soil-transmitted helminths (STH) and lymphatic filariasis (LF). Although the benefits of ALB-based MDA in the general population cannot be undermined, there can be severe consequences in certain groups, especially those with latent NCC. In this commentary, we discuss the effect it may have on such patients, and suggest potential solutions.
- Open Access
- 9 July 2019
- Published by Springer Nature in BMC Neurology
- Vol. 19 (1) , 1-9
Status of prehospital delay and intravenous thrombolysis in the management of acute ischemic stroke in Nepal
Intravenous thrombolysis has been recently introduced in Nepal for the management of acute ischemic stroke. Pre-hospital delay is one of the main reasons that hinder thrombolytic therapy. The objective of this study was to evaluate the status of prehospital delay and thrombolysis in Nepal. Data were prospectively collected from patients of both genders, age > 18 years who arrived at the emergency department (ED) with symptoms and neuroimaging findings consistent with an ischemic stroke. Patient data were obtained from ED form and standard questionnaires were used to assess factors resulting in prehospital delay. Modified Rankin scale and National Institute of Health stroke scale were used to assess the degree of disability and severity of stroke respectively. A total of 228 patients were enrolled in the study between August 2017 and August 2018. Only 46 (20.17%) patients arrived within the time frame for thrombolysis. Onset at daytime (OR: 4.07; 95% CI: 1.65–10.1; p = 0.001), stroke symptoms facial deviation (OR: 5.03; 95% CI: 2.47 to 10.26; p = 0.000) and speech disturbances (OR: 2.34; 95% CI: 1.06 to 5.1; p = 0.021), identification of stroke (OR: 22.36; 95% CI: 9.42–53.04;p = 0.000), rushing to ED after onset of symptoms (OR: 2.93; 95% CI: 1.5–5.7; p = 0.001), awareness of treatment of stroke (OR: 10.21; 95% CI: 4.8–21.6; p = 0.000), direct presentation (OR: 4.2; 95% CI: 2.09–8.66; p = 0.000), the distance less than 20 km (OR: 7.9; 95% CI: 3.8–16.5; p = 0.000), and education above high school (OR:4.85; 95% CI: 2.2–10.5; p = 0.000) were associated with early arrival. Heavy traffic, income below 1000 USD per annum and diabetes mellitus were associated with delayed arrival to ED. Out of 46 early arrival patients, only 30 patients (13.15%) received tissue plasminogen activator during the study period, while others were deprived because of their inability to afford the treatment cost. Community-based intervention to spread awareness, establishing comprehensive stroke centers, training specialists, improving emergency services, establishment of telestroke facilities and encouraging the use of low-cost tenecteplase as an alternative to alteplase can help improve care for stroke patients in Nepal.
- 9 July 2019
- Published by Springer Nature in BMC Neurology
- Vol. 19 (1) , 1-9
Open AccessStatus of prehospital delay and intravenous thrombolysis in the management of acute ischemic stroke in Nepal
Intravenous thrombolysis has been recently introduced in Nepal for the management of acute ischemic stroke. Pre-hospital delay is one of the main reasons that hinder thrombolytic therapy. The objective of this study was to evaluate the status of prehospital delay and thrombolysis in Nepal. Data were prospectively collected from patients of both genders, age > 18 years who arrived at the emergency department (ED) with symptoms and neuroimaging findings consistent with an ischemic stroke. Patient data were obtained from ED form and standard questionnaires were used to assess factors resulting in prehospital delay. Modified Rankin scale and National Institute of Health stroke scale were used to assess the degree of disability and severity of stroke respectively. A total of 228 patients were enrolled in the study between August 2017 and August 2018. Only 46 (20.17%) patients arrived within the time frame for thrombolysis. Onset at daytime (OR: 4.07; 95% CI: 1.65–10.1; p = 0.001), stroke symptoms facial deviation (OR: 5.03; 95% CI: 2.47 to 10.26; p = 0.000) and speech disturbances (OR: 2.34; 95% CI: 1.06 to 5.1; p = 0.021), identification of stroke (OR: 22.36; 95% CI: 9.42–53.04;p = 0.000), rushing to ED after onset of symptoms (OR: 2.93; 95% CI: 1.5–5.7; p = 0.001), awareness of treatment of stroke (OR: 10.21; 95% CI: 4.8–21.6; p = 0.000), direct presentation (OR: 4.2; 95% CI: 2.09–8.66; p = 0.000), the distance less than 20 km (OR: 7.9; 95% CI: 3.8–16.5; p = 0.000), and education above high school (OR:4.85; 95% CI: 2.2–10.5; p = 0.000) were associated with early arrival. Heavy traffic, income below 1000 USD per annum and diabetes mellitus were associated with delayed arrival to ED. Out of 46 early arrival patients, only 30 patients (13.15%) received tissue plasminogen activator during the study period, while others were deprived because of their inability to afford the treatment cost. Community-based intervention to spread awareness, establishing comprehensive stroke centers, training specialists, improving emergency services, establishment of telestroke facilities and encouraging the use of low-cost tenecteplase as an alternative to alteplase can help improve care for stroke patients in Nepal.
- Open Access
- 31 August 2018
- Published by Institute of Medicine, Nepal in Journal of Institute of Medicine Nepal
- Vol. 40 (2) , 27-32
Spectrum of Cryptococcal Meningoencephalitis in Tertiary Hospital in Nepal
Introduction: Cryptococcal meningoencephalitis is the most frequently encountered manifestation of cryptococcosis and prevalent throughout the globe. The majority of patient suffering from cryptococcosis is immunocompromised and AIDS account for most of the case. We aimed to determine the spectrum of cryptococcal meningoencephalitis at Tribhuvan University Teaching Hospital (TUTH), Kathmandu, Nepal. Methods: A retrospective study was performed among all the patients (n=15) who were admitted with cryptococcal meningoencephalitis at TUTH over a period of one fiscal year July 2017 to June 2018. Data on patient’s demography, history, complaints, clinical findings, neuroimaging, cerebrospinal fluid (CSF) investigation, hospital medication information, complications, mortality and Left Against Medical Advise (LAMA) were extracted from patient medication records of the hospital. Descriptive statistics was performed using IBM-SPSS 20.0. Results: Of total 15 patients with Cryptococcal meningoencephalitis, majority (9, 60%) had HIV infection. The most common complaints were vomiting (12, 80%) and headache (11, 73%) and clinical findings showed meningeal irritation (8, 53%) and papilledema (4, 27%). Only two neuroimagings among all patients were abnormal. CSF investigation depicted high total cell count (>5cells/mm3), high protein (>45 mg/dl) and positive cryptococcal antibody in all patients while lymphocytic predominance and lower sugar levels (<3 mmol/dl) in 93% along with ADA of <10 U/L in 67%. Amphotericin-B (mean duration 17 days) and fluconazole antifungals were used in all the patients. Twenty seven percent patients died during hospital stay. Pancytopenia, hydrocephalus and hospital acquired pneumonia were observed in 7 percent of patient from each group and 13 percent of cases left against medical advice. Conclusion: Cryptococcal meningoencephalitis is common in People Living with HIV (PLHIV) and caused substantial mortality.
- 31 August 2018
- Published by Institute of Medicine, Nepal in Journal of Institute of Medicine Nepal
- Vol. 40 (2) , 27-32
Open AccessSpectrum of Cryptococcal Meningoencephalitis in Tertiary Hospital in Nepal
Introduction: Cryptococcal meningoencephalitis is the most frequently encountered manifestation of cryptococcosis and prevalent throughout the globe. The majority of patient suffering from cryptococcosis is immunocompromised and AIDS account for most of the case. We aimed to determine the spectrum of cryptococcal meningoencephalitis at Tribhuvan University Teaching Hospital (TUTH), Kathmandu, Nepal. Methods: A retrospective study was performed among all the patients (n=15) who were admitted with cryptococcal meningoencephalitis at TUTH over a period of one fiscal year July 2017 to June 2018. Data on patient’s demography, history, complaints, clinical findings, neuroimaging, cerebrospinal fluid (CSF) investigation, hospital medication information, complications, mortality and Left Against Medical Advise (LAMA) were extracted from patient medication records of the hospital. Descriptive statistics was performed using IBM-SPSS 20.0. Results: Of total 15 patients with Cryptococcal meningoencephalitis, majority (9, 60%) had HIV infection. The most common complaints were vomiting (12, 80%) and headache (11, 73%) and clinical findings showed meningeal irritation (8, 53%) and papilledema (4, 27%). Only two neuroimagings among all patients were abnormal. CSF investigation depicted high total cell count (>5cells/mm3), high protein (>45 mg/dl) and positive cryptococcal antibody in all patients while lymphocytic predominance and lower sugar levels (<3 mmol/dl) in 93% along with ADA of <10 U/L in 67%. Amphotericin-B (mean duration 17 days) and fluconazole antifungals were used in all the patients. Twenty seven percent patients died during hospital stay. Pancytopenia, hydrocephalus and hospital acquired pneumonia were observed in 7 percent of patient from each group and 13 percent of cases left against medical advice. Conclusion: Cryptococcal meningoencephalitis is common in People Living with HIV (PLHIV) and caused substantial mortality.
- Open Access
- 9 February 2018
- Published by Springer Nature in Cureus
- Vol. 10 (2) , e2178
Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country–Nepal: Cost, Efficacy, and Safety
Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered, mutant tissue plasminogen activator, is an alternative thrombolytic agent. The economic feasibility of stroke treatment has been a matter of huge debate and discussion thus far. The use of thrombolytics for the management of ischemic stroke has recently begun in Nepal. In low-income countries like Nepal, where the per capita income falls at just $691.7 and 25.2% of the population are under the poverty line, stroke patients cannot meet treatment expenses. Tenecteplase is easily available (for the management of acute coronary syndrome) in tertiary-level hospitals of Nepal and the price quote of tenecteplase ($450) is half the price of alteplase ($1000). In emergency cases, sometimes, the cost of alteplase can be greater than the patient can afford and they can't undergo thrombolysis even after arriving on time. However, evidence exists that supports the use of other alternatives (tenecteplase), which are also effective in the management of acute ischemic stroke. In this article, we examined current evidence for the efficacy and safety of tenecteplase when compared to alteplase. This review will make neurologists in Nepal familiar with the efficacy and safety of tenecteplase in comparison with alteplase since it is common for patients to not be able to afford the expensive alteplase, which makes guideline-based practice impossible some times.
- 9 February 2018
- Published by Springer Nature in Cureus
- Vol. 10 (2) , e2178
Open AccessTenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country–Nepal: Cost, Efficacy, and Safety
Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered, mutant tissue plasminogen activator, is an alternative thrombolytic agent. The economic feasibility of stroke treatment has been a matter of huge debate and discussion thus far. The use of thrombolytics for the management of ischemic stroke has recently begun in Nepal. In low-income countries like Nepal, where the per capita income falls at just $691.7 and 25.2% of the population are under the poverty line, stroke patients cannot meet treatment expenses. Tenecteplase is easily available (for the management of acute coronary syndrome) in tertiary-level hospitals of Nepal and the price quote of tenecteplase ($450) is half the price of alteplase ($1000). In emergency cases, sometimes, the cost of alteplase can be greater than the patient can afford and they can't undergo thrombolysis even after arriving on time. However, evidence exists that supports the use of other alternatives (tenecteplase), which are also effective in the management of acute ischemic stroke. In this article, we examined current evidence for the efficacy and safety of tenecteplase when compared to alteplase. This review will make neurologists in Nepal familiar with the efficacy and safety of tenecteplase in comparison with alteplase since it is common for patients to not be able to afford the expensive alteplase, which makes guideline-based practice impossible some times.